Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia
Version of Record online: 4 FEB 2008
Copyright © 2008 Wiley-Liss, Inc.
American Journal of Hematology
Volume 83, Issue 6, pages 446–450, June 2008
How to Cite
Hussein, K., Jahagirdar, B., Gupta, P., Burns, L., Larsen, K. and Weisdorf, D. (2008), Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia. Am. J. Hematol., 83: 446–450. doi: 10.1002/ajh.21133
- Issue online: 2 MAY 2008
- Version of Record online: 4 FEB 2008
- Manuscript Accepted: 28 NOV 2007
- Manuscript Revised: 23 OCT 2007
- Manuscript Received: 15 MAY 2007
We retrospectively analyzed 194 previously untreated acute myeloid leukemia (AML) patients to evaluate the role of Day 14 bone marrow (BM) biopsy in predicting complete remission (CR). Sixty-seven percent received induction therapy. Achieving Day 14 BM ≤5% blasts was strongly predictive of Day 28 CR with 90% sensitivity and 79% positive predictive value; but weak 43% specificity and 29% negative predictive value. Day 14 BM biopsy is highly sensitive in predicting CR, but did not predict overall survival. Some patients with BM blast >5% at Day 14 may still achieve a Day 28 CR, and not necessarily need reinduction therapy though high risk cytochemical or cytogenetic phenotype predicts a need for retreatment. Am. J. Hematol., 2008. © 2008 Wiley-Liss, Inc.